Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2011 Jan 24;2:8. doi: 10.4103/2152-7806.76145

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © 2011 Kai Y

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PMC Copyright notice

3A: Pretreatment MRA shows a stenotic lesion (85%) at the left M1 (white arrow)

3B: Pretreatment SPECT shows no laterality in CBF at rest.

3C: Pretreatment SPECT shows hypovasoreactivity in the left temporo-occipital region after acetazolamide challenge (white arrow head).

3D: MRA obtained 6 months after the start of cilostazol treatment shows improvement of the stenotic lesion (30%) at the left M1 (white arrow).

3E: MRA acquired 12 months after the start of cilostazol treatment shows improvement of the stenotic lesion (20%) at the left M1 (white arrow).

3F: SPECT obtained 12 months after the start of cilostazol treatment shows increased CBF in the left cerebral hemisphere.

3G: SPECT obtained 12 months after the start of cilostazol treatment shows CBF improvement in the left cerebral hemisphere after acetazolamide challenge (white arrowhead).